GSK unveiled a three-year cost-cutting program intended to save about £1.9 billion (roughly $2.5 billion) per year as the company braces for a major patent cliff affecting parts of its HIV franchise. The company said the restructuring will simplify the organization and support capital reallocation toward specialty medicines, including priority research projects. GSK indicated job cuts are expected, while also planning a more targeted structure of new roles. The company cited shifts toward AI technology and streamlining of supply chains and support services as drivers of the savings. The timing is particularly sensitive: GSK expects losses of patents between 2028 and 2030 for dolutegravir, which generated more than $5 billion in sales last year. Management highlighted a pipeline and launch slate—plus recent dealmaking in oncology—to bridge the gap. The restructuring announcement adds a familiar but high-stakes layer to GSK’s capital strategy: cost reduction to fund pipeline execution while facing major revenue downside from expiring protections.